These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16914592)

  • 1. Cetrorelix suppression test to assess the source of androgen overproduction in postmenopausal hirsutism.
    de Boer H; de Man M; de Bruyn K; van Sorge A
    Eur J Endocrinol; 2006 Sep; 155(3):391-3. PubMed ID: 16914592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetrorelix suppression test in the diagnostic work-up of severe hyperandrogenism in adolescence.
    de Man M; Derksen E; Pieters G; de Boer H
    J Pediatr Endocrinol Metab; 2008 Sep; 21(9):905-9. PubMed ID: 18924583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
    Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
    Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actions of gonadotropin-releasing hormone analogues in pituitary gonadotrophs and their modulation by ovarian steroids.
    Weiss JM; König SJ; Polack S; Emons G; Schulz KD; Diedrich K; Ortmann O
    J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):118-26. PubMed ID: 16891115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea.
    Berardelli R; Gianotti L; Karamouzis I; Picu A; Giordano R; D'Angelo V; Zinnà D; Lanfranco F; Ghigo E; Arvat E
    Gynecol Endocrinol; 2011 Oct; 27(10):753-8. PubMed ID: 21204607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone and postmenopausal flushing.
    de Boer H; van Gastel P; van Sorge A
    N Engl J Med; 2009 Sep; 361(12):1218-9. PubMed ID: 19759388
    [No Abstract]   [Full Text] [Related]  

  • 9. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of a small, androgenizing Brenner cell tumor in a postmenopausal woman aided by laparoscopic salpingo-oophorectomy. A case report.
    Silva PD; Caplan RH; Virata RL
    J Reprod Med; 2003 May; 48(5):381-3. PubMed ID: 12815914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test.
    Wajchenberg BL; Achando SS; Okada H; Czeresnia CE; Peixoto S; Lima SS; Goldman J
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1204-10. PubMed ID: 3760120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hirsutism and virilism in women.
    Kirschner MA
    Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone receptor antagonist may reduce postmenopausal flushing.
    van Gastel P; van der Zanden M; Telting D; Filius M; Bancsi L; de Boer H
    Menopause; 2012 Feb; 19(2):178-85. PubMed ID: 21926922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
    Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
    J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.